Avanço Significativo no Combate ao Cancro Pancreático
Avanço Significativo no Combate ao Cancro Pancreático
aitech.pt
aitech.pt
Spanish Researchers Eliminate Pancreatic Tumors in Mice
Significant Advance in the Fight Against Pancreatic Cancer
Spanish researchers from the National Center for Cancer Research (CNIO), led by Mariano Barbacid, have announced a groundbreaking milestone in the battle against pancreatic cancer: the complete elimination of pancreatic tumors in mouse models using a triple therapy approach. This advance offers great hope for a cancer type that traditionally has a five-year survival rate of only 10-13% due to treatment resistance and late diagnosis.
The Triple Therapy
The therapy developed by Barbacid’s team combines three drugs that simultaneously target three critical signaling pathways, which are dependent on the mutated KRAS gene, present in about 95% of cases of pancreatic ductal adenocarcinoma (PDAC), the most common and lethal form of this disease. The three targeted pathways are:
- KRAS: The gene responsible for transmitting growth signals to cells.
- EGFR (Epidermal Growth Factor Receptor): Important in signaling for cell growth.
- STAT3: A protein involved in the survival of cancer cells.
This multi-targeted approach prevents tumors from adapting through alternative pathways, a limitation often observed in single-agent treatments.
Experimental Results
The study’s results are promising and include:
- Complete Tumor Regression: Tumors induced by the implantation of cells into the pancreas of mice, mimicking human disease, were completely regressed.
- Variability Across Models: Success was demonstrated in genetically modified mice with KRAS and TP53 mutations, orthotopic transplants, and patient-derived xenografts (PDX).
- No Recurrences: After more than 200 days, no recurrences were observed, and the treatment was well tolerated, with only mild side effects like weight loss and skin irritation.
The findings were published in the journal Proceedings of the National Academy of Sciences (PNAS), where researchers emphasize that “these results should guide the development of new clinical trials that may benefit patients with PDAC.”
Implications and Future Directions
Despite the excitement surrounding this advancement, it’s important to recognize that these results were obtained in mice, and experts caution that the translation to humans requires further optimization. Mouse models do not always accurately predict human outcomes, and clinical trials are yet to be developed.
Final Considerations
- Promising Scientific Advancement: The triple therapy represents a significant breakthrough in the fight against one of the deadliest cancer types, offering new hope for the future.
- Caution in Human Application: The translation of these results to humans still requires many research and development steps before a viable treatment can be discussed.
Summary Table of Results
| Aspect | Details |
|---|---|
| Type of Cancer | Pancreatic ductal adenocarcinoma (PDAC) |
| Models Utilized | Genetically modified mice, orthotopic transplants, PDX |
| Results | Tumors eliminated, no recurrences after 200 days |
| Side Effects | Mild, including weight loss and skin irritation |
| Publication | Proceedings of the National Academy of Sciences (PNAS) |
This study opens new doors in the treatment of pancreatic cancer and, if successful in future clinical trials, could change the course of the disease for many affected patients.
Sources
- NTD - Pancreatic Cancer Eliminated in Mice with Triple Therapy
- Times of India - Spanish Scientist Finds Cure for Pancreatic Cancer
- Fox 4 News - Scientists Cure Pancreatic Cancer in Mice
- Lynnwood Times - Study on Pancreatic Tumors
- Euronews - Scientists Achieve Tumor Regression in Breakthrough Study
- Drug Target Review - Drug Trio Found to Block Tumor Resistance
- CNIO - Complete Elimination of Pancreatic Tumors in Mice
Share this post
Like this post? Share it with your friends!